Skip to main content

Pancrelipase Dosage

Medically reviewed by Drugs.com. Last updated on Jul 5, 2022.

Applies to the following strengths: 10,000 units-32,000 units-42,000 units; 15,000 units-47,000 units-63,000 units; 20,000 units-63,000 units-84,000 units; 3000 units-10,000 units-14,000 units; 40,000 units-126,000 units-168,000 units; 5000 units-17,000 units-24,000 units; 25,000 units-79,000 units-105,000 units; 8000 units-30,000 units-30,000 units; 16,800 units-70,000 units-70,000 units/0.7 g; 3000 units-9500 units-15,000 units; 5000 units-18,750 units-16,600 units; 6000 units-19,000 units-30,000 units; 10,000 units-37,500 units-33,200 units; 12,000 units-38,000 units-60,000 units; 20,000 units-75,000 units-66,400 units; 24,000 units-76,000 units-120,000 units; 36,000 units-114,000 units-180,000 units; 4500 units-25,000 units-20,000 units; 4000 units-12,000 units-12,000 units; 10,000 units-30,000 units-30,000 units; 16,000 units-48,000 units-48,000 units; 20,000 units-44,000 units-56,000 units; 5000 units-20,000 units-20,000 units; 12,000 units-24,000 units-24,000 units; 1200 units-15,000 units-15,000 units; 2400 units-30,000 units-30,000 units; 18,000 units-58,500 units-58,500 units; 12,000 units-39,000 units-39,000 units; 20,000 units-65,000 units-65,000 units; 16,000 units-60,000 units-60,000 units; 4000 units-25,000 units-20,000 units; 30 mg-2 mg-25 mg-6 mg; 11,000 units-30,000 units-30,000 units; 5000 units-17,000 units-27,000 units; 10,000 units-34,000 units-55,000 units; 15,000 units-51,000 units-82,000 units; 20,000 units-68,000 units-109,000 units; 3000 units-10,000 units-16,000 units; 25,000 units-85,000 units-136,000 units; 40,000 units-136,000 units-218,000 units; 4200 units-24,600 units-14,200 units; 10,500 units-61,500 units-35,500 units; 16,800 units-98,400 units-56,800 units; 21,000 units-83,900 units-54,700 units; 2600 units-10,850 units-6200 units; 13,800 units-27,600 units-27,600 units; 23,000 units-46,000 units-46,000 units; 20,700 units-41,400 units-41,400 units; 10,440 units-39,150 units-39,150 units; 20,880 units-78,300 units-78,300 units; 8000 units-40,000 units-45,000 units; 4000 units-25,000 units-25,000 units; 16,000 units-52,000 units-52,000 units; 4000 units-14,375 units-15,125 units; 8000 units-28,750 units-30,250 units; 16,000 units-57,500 units-60,500 units; 24,000 units-86,250 units-90,750 units; 2600 units-15,200 units-8800 units; 37,000 units-97,300 units-149,900 units; 60,000 units-189,600 units-252,600 units

Usual Adult Dose for Pancreatic Exocrine Dysfunction

Initial dose: 500 lipase units/kg orally per meal
Maintenance dose: Up to 2500 lipase units/kg orally per meal
Maximum dose: 10,000 lipase units/kg/day OR 4000 lipase units/gram fat ingested per day

Comments:


Use: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Usual Adult Dose for Cystic Fibrosis

Initial dose: 500 lipase units/kg orally per meal
Maintenance dose: Up to 2500 lipase units/kg orally per meal
Maximum dose: 10,000 lipase units/kg/day OR 4000 lipase units/gram fat ingested per day

Comments:


Use: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Usual Adult Dose for Chronic Pancreatitis

Initial dose: 500 lipase units/kg orally per meal
Maintenance dose: Up to 2500 lipase units/kg orally per meal
Maximum dose: 10,000 lipase units/kg/day OR 4000 lipase units/gram fat ingested per day

Comments:


Use: In combination with a PPI for the treatment of exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatectomy

Usual Pediatric Dose for Pancreatic Exocrine Dysfunction

Up to 12 months: 2000 to 4000 lipase units per 120 mL of formula or breastfeeding

Older than 12 months to younger than 4 years:


4 years and older:

Comments:

Use: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Usual Pediatric Dose for Cystic Fibrosis

Up to 12 months: 2000 to 4000 lipase units per 120 mL of formula or breastfeeding

Older than 12 months to younger than 4 years:


4 years and older:

Comments:

Use: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions

Renal Dose Adjustments

Renal dysfunction: Use with caution; healthcare providers should consider monitoring uric acid levels.

Liver Dose Adjustments

Data not available

Dose Adjustments

Initial doses:


Maintenance doses: Maintenance doses should be determined by clinical symptoms, degree of steatorrhea, and the fat content of the diet.

Patients with gout and/or hyperuricemia: Use with caution.

Persistent signs/symptoms of steatorrhea:

High doses:

Precautions

CONTRAINDICATIONS: None

Safety and efficacy of some tablet formulations have not been established in pediatric patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.